[Skip to Navigation]
Sign In
March 5, 2020

A New Therapeutic Era for Metastatic Renal Cell Carcinoma: Call for a New Prognostic Model

Author Affiliations
  • 1Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
JAMA Oncol. 2020;6(5):633-634. doi:10.1001/jamaoncol.2019.6862

The therapeutic landscape for metastatic renal cell carcinoma (mRCC) has evolved over 3 eras, including the cytokine, targeted therapy, and current immune checkpoint inhibitor (ICI) eras. The contemporary ICI era was introduced by the CheckMate 025 trial, which led to the US Food and Drug Administration approval of nivolumab for treating mRCC in 2015.1 Since then, the use of ICI has continued to markedly affect the treatment paradigm for mRCC.

Add or change institution